Health Care

Medtronic PLC’s Q4 2025 earnings reveal how its expanding IoMT strategy fuels steady growth, positioning it ahead of rivals like GE Healthcare and Johnson & Johnson.

Explore how Daiichi Sankyo’s oncology and immunotherapy strategy drives 10‑year NPV of $2.5 billion, tackles TNBC patent cliffs, and targets M&A for growth.

Galderma’s latest ASDS data show Restylane, Sculptra and Relfydess deliver strong, lasting volume with minimal side‑effects—evidence that could shape future aesthetic practice.

Veeva’s expanded Basics Suite boosts biotech operations with cloud‑native, compliant, scalable tools—enhancing security, analytics and faster regulatory submissions.

Alnylam’s siRNA strategy blends cutting‑edge RNA tech with value‑based pricing and HTA wins to capture high‑margin markets, from cardiology to Huntington’s disease.

Gilead’s ARTISTRY‑1 Phase 3 trial shows single‑tablet bictegravir/lenacapavir matches multi‑tablet regimens for virologic suppression, with similar safety and lower pill burden, boosting adherence and cost savings for HIV patients.

Merck’s $9 billion buy of Cidara Therapeutics adds a Phase‑III influenza prophylactic, boosting its antiviral pipeline and protecting against patent cliffs while promising 3.5‑year payback.

Discover why Natera’s upgraded stock‑price target reflects its winning cfDNA platform, FDA‑cleared NIPT and oncology liquid biopsies, and future growth plans.

Abbott Laboratories’ latest earnings show modest growth, but deep dive reveals regulatory, AI‑driven diagnostics, supply‑chain and digital health risks and opportunities shaping future upside.

DaVita’s upcoming Wolfe Research fireside chat will reveal how its tech‑driven, value‑based strategies and site expansion plans drive superior margins and future growth.